Inhalation Sciences Sweden AB (ISAB) announced that in September 2022 it was awarded an FDA BAA (Broad Agency Announcement) contract for a research project evaluating the discriminative power of its DissolvIt in vitro dissolution technology. The project has now had its Kick-off meeting and is underway. ISAB has communicated previously on this project, most recently on 15 September 2022.

The objective of contract 75F40122C00197 is to evaluate the discriminative power of ISAB's DissolvIt technology by comparing drug formulations, aimed for administration via inhalation, with small differences. The project scope also includes in vitro in vivo correlation (IVIVC). The proposed work was approved by the FDA Center for Drug Evaluation and Research (CDER).